India Serological Testing Market 2024–2033

Reports Description

India Serological Testing Market was valued at USD 276.6 Million in 2024 and is expected to reach USD 798.2 Million by 2033, at a CAGR of 14.1% during the forecast period 2024 – 2033.

Serological testing involves analysing blood serum to detect the presence of antibodies, which are proteins produced by the immune system in response to pathogens like viruses or bacteria. These tests help diagnose past or present infections, determine immune status, and assess vaccine effectiveness.

India Serological Testing Market: Growth Factors

Growing blood donation initiatives

Growing blood donation initiatives in India are instrumental in driving the serological testing market due to their crucial role in ensuring the safety and efficacy of blood transfusions. As these initiatives encourage more individuals to donate blood voluntarily, there is a corresponding increase in the volume of donated blood that needs to be screened for infectious diseases and other health markers.

Serological testing plays a pivotal role in this process by detecting antibodies, antigens, and other markers present in the blood that could indicate the presence of diseases such as HIV, hepatitis, syphilis, and malaria.

With more people participating in blood donation drives, there is a higher demand for serological testing services to screen donated blood for these infectious agents, ensuring that only safe blood products are transfused to patients in need.

Consequently, the surge in blood donation activities not only addresses the ongoing demand for blood transfusions but also catalyses the growth of the serological testing market in India, as healthcare facilities and blood banks increasingly rely on these tests to maintain the quality and safety of their blood supply.

This symbiotic relationship between blood donation initiatives and serological testing services underscores the critical role they play in advancing public health efforts and improving healthcare outcomes across the country.

Growing prevalence of infectious diseases

The growing prevalence of infectious diseases in India has been a key driver behind the expansion of the serological testing market in the country. Serological testing plays a crucial role in diagnosing infectious diseases by detecting specific antibodies produced by the immune system in response to pathogens such as bacteria or viruses.

With India facing persistent challenges related to infectious diseases such as tuberculosis, HIV/AIDS, hepatitis, dengue, and emerging threats like COVID-19, there has been an increased demand for serological testing to facilitate accurate diagnosis, disease surveillance, and epidemiological studies.

Furthermore, the large population density, inadequate healthcare infrastructure in certain regions, and high burden of communicable diseases create a pressing need for efficient and scalable diagnostic solutions.

Serological tests offer advantages such as relatively low cost, rapid turnaround time, and ease of implementation, making them particularly suitable for widespread screening efforts and population-based studies.

As the burden of infectious diseases continues to evolve and new pathogens emerge, the demand for serological testing is expected to further drive market growth, prompting advancements in technology, testing methodologies, and the development of novel diagnostic assays tailored to the Indian healthcare context.

India Serological Testing Market: Restraints

High cost of diagnostic tests

The high cost of diagnostic tests presents a significant barrier to the growth of India’s serological testing market. Serological tests, which detect antibodies in the blood to diagnose various infectious diseases, are crucial for disease surveillance, outbreak management, and patient care.

However, the prohibitive costs associated with these tests often deter individuals, particularly those from lower socioeconomic backgrounds, from seeking timely diagnosis and treatment. This disparity in access to serological testing exacerbates existing healthcare inequalities and contributes to delayed detection and management of infectious diseases, leading to potential public health challenges.

Moreover, the high cost of diagnostic tests places a burden on the healthcare system, limiting its capacity to effectively address public health concerns and allocate resources efficiently. Consequently, efforts to reduce the cost of serological testing through government subsidies, public-private partnerships, or technological innovations are essential to enhance accessibility, improve healthcare outcomes, and mitigate the impact of infectious diseases in India.

India Serological Testing Market: Opportunities

Increasing usage of chemiluminescence immunoassay

The increasing usage of chemiluminescence immunoassay (CLIA) is a significant driver propelling the growth of India’s serological testing market. CLIA offers several advantages over traditional immunoassay techniques, such as enzyme-linked immunosorbent assay (ELISA), including higher sensitivity, faster results, and greater specificity.

These benefits make CLIA particularly well-suited for serological testing, which involves the detection of antibodies in blood serum. With the rising prevalence of infectious diseases, autoimmune disorders, and chronic conditions in India, there is a growing demand for accurate and efficient serological testing methods.

CLIA’s ability to detect low concentrations of antibodies with high precision makes it a preferred choice for diagnosing various diseases and monitoring immune responses. Furthermore, the scalability of CLIA platforms allows for high-throughput testing, enabling laboratories to process large numbers of samples quickly and cost-effectively.

As healthcare facilities in India continue to modernize and prioritize efficient diagnostic solutions, the adoption of CLIA technology is expected to drive substantial growth in the serological testing market, meeting the increasing demand for reliable and timely antibody detection.

India Serological Testing Market: Segmentation Analysis

India Serological Testing market is segmented by product, application and region.  Based on product, the market is classified into instruments, and reagents & consumables. Reagents & Consumables dominated the market in 2023 with a market share of 80.0% and is expected to keep its dominance during the forecast period 2024-2033.

Reagents and consumables play a pivotal role in driving the serological testing market in India, contributing to its growth and sustainability. These essential components are indispensable for conducting various serological tests, such as enzyme-linked immunosorbent assays (ELISA), Western blotting, and rapid tests, which are crucial for diagnosing infectious diseases, and autoimmune disorders, and monitoring therapeutic interventions.

The demand for serological testing reagents and consumables is propelled by several factors, including the rising prevalence of infectious diseases like HIV/AIDS, hepatitis, and COVID-19, as well as the increasing awareness and accessibility of healthcare services across the country.

Additionally, advancements in biotechnology and diagnostics have led to the development of novel serological assays, driving the need for specialized reagents and consumables tailored to these assays. Moreover, government initiatives aimed at expanding healthcare infrastructure, coupled with growing investments in research and development, further stimulate the market by fostering innovation and product development.

However, challenges such as regulatory constraints, pricing pressures, and supply chain disruptions can hinder market growth.

Based on application, the market is classified into Hepatitis C, Hepatitis B, HIV, Malaria, Syphilis, Blood Group Typing (BGT), and Others. Malaria dominated the market in 2023 with a market share of 45.9% and is expected to keep its dominance during the forecast period 2024-2033.

The prevalence of malaria in India has catalysed a significant expansion in the country’s serological testing market. Malaria, a mosquito-borne infectious disease caused by parasites of the Plasmodium genus, remains a major public health concern in India, particularly in regions with high humidity and rainfall, providing ideal breeding grounds for mosquitoes.

Serological testing plays a crucial role in the diagnosis and management of malaria, enabling healthcare professionals to detect the presence of malaria antibodies or antigens in the patient’s blood. With India’s vast population and diverse geographic landscape, the demand for accurate and efficient diagnostic tools for malaria is substantial.

Consequently, the market for serological testing products, including rapid diagnostic tests (RDTs) and enzyme-linked immunosorbent assays (ELISAs), has experienced robust growth. This growth is further fuelled by government initiatives aimed at combating malaria, which often involve extensive screening and surveillance efforts.

Additionally, advancements in technology have led to the development of more sensitive and specific serological tests, enhancing their utility in malaria-endemic regions. As a result, the malaria-driven demand for serological testing has not only expanded the market size but also fostered innovation, ultimately improving the effectiveness of malaria control and prevention efforts in India.

Report Scope

India Serological Testing Market: Regional Analysis

India Serological Testing market is segmented into East India, West India, North India and South India. West India dominated the India Serological Testing market in 2023 with a market share of 41.4% and is expected to keep its dominance during the forecast period 2024-2033.

The West India region has played a significant role in propelling India’s serological testing market forward through various factors. With a robust healthcare infrastructure and a proactive approach towards medical advancements, West India has emerged as a key contributor to the adoption of serological testing technologies across the nation.

Major metropolitan cities like Mumbai and Pune, known as hubs for medical research and innovation, have facilitated the widespread implementation of serological testing methodologies.

Additionally, the region’s dense population and diverse demographic profile have created a substantial demand for diagnostic solutions, driving the growth of the serological testing market. Furthermore, the presence of leading healthcare institutions, research centers, and pharmaceutical companies in West India has fostered collaboration and investment in serological testing research and development initiatives.

This has led to the introduction of advanced serological assays and diagnostic platforms tailored to address the specific healthcare challenges prevalent in the region, such as infectious diseases and chronic conditions.

Overall, West India’s proactive healthcare ecosystem, coupled with its demographic dynamics and collaborative research environment, has propelled the expansion and innovation of serological testing, positioning the region as a key driver of growth in India’s serological testing market.

India Serological Testing Market: Recent Developments

• In November 2021, Siemens Healthineers AG and Hemogenomics funded a clinical trial for a comparative evaluation of the ADVIA Centaur XP chemiluminescence system for the screening process of HIV, HCV, and Syphilis in blood donors from India.

• In April 2019, Mylab Discovery Solutions launched NATSpert, an Individual Donor Nucleic Acid test (ID-NAT) to screen HIV, HBV and HCV in donated blood.

List of the prominent players in the India Serological Testing Market:

• Serological Research Institute
• Chembio Diagnostics Inc
• Cellex
• Randox Laboratories Ltd
• Abbott
• Bio-Rad Laboratories Inc.
• BD
• Thermo Fisher Scientific Inc.
• Ortho Clinical Diagnostics
• Quest Diagnostics Incorporated
• Abcam Plc
• Hoffmann-La Roche Ltd.
• ELITechGroup
• Teleflex Incorporated
• Grifols S.A.
• Global Scientific Company
• Beckman Coulter Inc.
• BIOMEDOMICS INC.
• Creative Diagnostics
• Others

These key players are adopting various growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.

The India Serological Testing Market is segmented as follows:

By Product

• Instruments
• Reagents & Consumables

By Application

• Hepatitis C
• Hepatitis B
• HIV
• Malaria
• Syphilis
• Blood Group Typing (BGT)
• Others